❝ Key Takeaways
Omega-3s are proposed to reduce inflammation by lowering production of inflammatory proteins (TNF-α, IL-1β, IL-6).
These pathways are well-shown in laboratory and animal studies, but the clinical relevance in humans is less clearly established.
For joint pain and inflammation, the benefit is modest and inconsistent across patient populations.
For dry eye disease, two large clinical trials found no benefit from omega-3 supplementation.
For age-related macular degeneration (AMD), randomized trials have not shown a reduction in progression with supplements, but observational studies suggest higher blood DHA levels are associated with meaningfully lower AMD risk.
Want to understand the science behind these? Keep reading below 👇
📑 In This Issue
How might omega-3s affect inflammation?
Arthritis and joint pain
Dry eye disease
Age-related Macular degeneration (AMD)
Why people still feel better on fish oil
Should you try it?
The bottom line
Catch up on the rest of the series: Welcome to Pareto Life · Upcoming Series on Omega-3 · Issue 01 — Are Omega-3s good for everyone’s heart? · Issue 02 — Do Omega-3s reduce risk of dementia?
How Might Omega-3s Affect Inflammation?
Several biological pathways have been identified, however they have not yet translated into consistently clinically meaningful results in humans.
In cell and animal studies, EPA and DHA inhibit NF-κB, which is essentially a master switch for inflammation. If NF-κB is activated, it travels to the cell’s nucleus and turns on genes that produce inflammatory proteins like TNF-α, IL-1β, and IL-6.
Omega-3s also do something more interesting than just blocking inflammation: they generate molecules called specialized pro-resolving mediators (resolvins, protectins, maresins) that actively help resolve inflammation and support tissue repair.
So the biology is real. The question is whether that biology translates into something that is clinically impactful.
In blood tests, omega-3 supplementation does modestly lower inflammatory markers. Doses in the 1–3 g/day EPA+DHA range produce the most reliable effect especially in individuals with an elevated C-reactive protein (measure of inflammation). However the decline is modest at best and it is important to evaluate if a decrease in 0.4 mg/dL is a clinically meaningful decrease. Statistical significance does not always mean clinical significance.
Arthritis & Joint Pain: What the Evidence Shows
Multiple clinical trials and meta-analyses have tested omega-3s across different types of joint disease. The overall picture is more mixed than supplement marketing suggests, and the benefits are not universal.
❝ 📋 What the Key Trials Found
Rheumatoid Arthritis (RA)
A 2024 meta-analysis of 23 Randomized Controlled Trials (RCTs) of 1,420 patients found only small, statistically non-significant effects on pain. The authors rated the certainty of evidence as “very low/low.”
A separate 2024 meta-analysis of 18 RCTs which included 1,018 patients confirmed a reduction in tender joint count but showed no significant effect on overall disease activity scores like ESR or CRP. (ESR and CRP are blood proteins that measure inflammation.)
A 2022 meta-analysis of 30 RCTs found broader symptomatic benefit, particularly with marine sources at >2 g/day for 3–6 months, but the more conservative 2024 reviews above raise real questions about whether older positive findings were biased by inadequate blinding.
Osteoarthritis (OA)
The 2024 JAMA krill oil trial (Laslett et al., 262 patients, 2 g/day krill oil = 380 mg EPA + 200 mg DHA, 24 weeks) found no significant difference in knee pain versus placebo.
A separate meta-analysis of 6 osteoarthritis trials found significant pain reduction with omega-3s, but the authors noted high variability and rated the evidence as low quality.
The VITAL trial knee-pain substudy (n=1,398, mean follow-up 5.3 years, 1 g/day fish oil = 840 mg EPA+DHA) found no effect on function or stiffness.
Spondyloarthritis
A 2024 meta-analysis of 4 trials (245 patients) found no improvement in tender joints, swollen joints, pain, or function scores. All included studies were rated as having “some concerns” or high risk of bias.
The honest read for joints:
The strongest signal is for RA at higher doses (≥2 g/day for 3+ months), but the most rigorous recent meta-analyses are less enthusiastic than older ones. For OA and spondyloarthritis, the evidence is weak. None of this rules out a personal trial of fish oil for joint pain but it does mean you should set the expectation low and reassess at 3 months.
Eye Health: A Mixed Picture
The evidence for omega-3s and eye health splits cleanly into two stories: dry eye disease and macular degeneration.
Dry Eye Disease
Dry eye is a condition rooted in chronic inflammation that can be triggered when tears become saltier either because of reduced tear production or increased tear evaporation. Triggers include low humidity, allergies, contact lens wear, and extended screen time (which reduces blinking). When the eye surface is stressed, its cells release inflammatory proteins that damage the surface, and the damaged surface can no longer hold tears properly. That’s the cycle that perpetuates the problem.
The American Academy of Ophthalmology (AAO) Preferred Practice Pattern guidelines state that omega-3 fatty acid products “may be beneficial, though the evidence is insufficient to establish the effectiveness.”
❝ 📋 Clinical Trials: Omega-3s and Dry Eye
DREAM Study (2018) — the largest trial: 545 patients with moderate-to-severe dry eye received 3,000 mg/day EPA+DHA or placebo for 12 months. No significant difference in symptoms or any objective signs (corneal staining, tear break-up time, Schirmer test) between groups.
VITAL-DED Study (2022) — the prevention trial: 23,523 initially healthy adults received 1 g/day omega-3 (840 mg EPA+DHA) or placebo for a median of 5.3 years. No effect on incident dry eye disease diagnosis or severe dry eye symptoms.
Why does the AAO still recommend considering omega-3 for dry eye? Smaller studies have shown improvements in tear osmolarity, tear volume, and contact time of tears with the corneal surface. Pair that with the low risk of supplementation, the AAO concludes that a trial may be worthwhile.
AMD is a condition where inflammation drives degeneration of the macula, which is the central part of the retina. As it progresses, it leads to vision loss. DHA is the most abundant fatty acid in the retina, and as we just covered, omega-3 can reduce inflammation. So the mechanistic case for omega-3 in AMD is plausible.
The trial evidence, however, is inconsistent. Randomized trials have not shown benefit from supplementation, while observational data consistently shows an association between higher omega-3 blood levels and lower AMD risk. There are also genes associated with AMD (CFH, complement factor H and ARMS2/HTRA1), but trials have not consistently shown that genetic carriers benefit more from omega-3 supplements.
❝ 👁️ What the Research Shows on AMD
AREDS2 Trial (2013, JAMA): 4,203 high-risk patients took 1 g/day EPA+DHA for 5 years. Result: no reduction in AMD progression. A 10-year follow-up confirmed the same null finding.
NAT2 Study (2013): Overall, no significant difference in AMD progression. A post-hoc subgroup analysis found that patients who achieved the highest blood levels of EPA+DHA had a 68% lower risk of choroidal neovascularization, but this finding has not been confirmed in other trials.
UK Biobank (2025, 258,350 people, 12.9-year follow-up): Higher plasma omega-3 levels were associated with lower AMD risk, and Mendelian randomization analyses suggest the relationship may be causal rather than purely correlational. Importantly, this was based on blood levels and dietary intake — not supplementation trials.
The honest read for eyes:
For dry eye, the supplement form of omega-3 has not delivered in large RCTs but it’s low-risk and the AAO leaves the door open. For AMD, the supplement trials are null but the dietary signal is real. Taking a fish oil capsule to reduce risk of AMD is harder to support.
So Why Do So Many People Feel Better on Fish Oil?
Three honest possibilities and they aren’t mutually exclusive:
Baseline status may matter (though this is more hypothesis than proof for joints). The VITAL inflammation substudy showed omega-3 modestly lowered an inflammatory marker called CRP only in people with low baseline fish intake, supporting the idea. Of note, no arthritis trial has formally confirmed a low-baseline subgroup effect.
Dose and form matter. 1 g/day is the marketing-friendly number. The trials with the cleanest signal use 2–4 g/day of EPA+DHA.
Inflammation is upstream of a lot of things. Modestly lowering CRP and IL-6 may have downstream benefits. By reducing inflammmation, impacts such as may improve recovery, sleep, and post-exercise soreness in ways that don’t show up in a joint-pain scale but do show up subjectively.
Should You Try It?
For most of the conditions covered in this issue: joint pain, dry eye, AMD risk, there is no real harm in trying omega-3 supplementation. EPA and DHA at 1–3 g/day are well-tolerated in the trials we discussed.
But two things matter just as much as the low-risk profile:
The evidence is not strong. For rheumatoid arthritis the signal is modest; for osteoarthritis, spondyloarthritis, and dry eye disease the most rigorous recent trials have been negative or inconclusive; for AMD progression, the supplement trials are null. A personal trial of fish oil is reasonable, but you should set the expectation low and reassess at three months.
Omega-3 supplementation does not replace standard-of-care treatment. It is an adjunct, not a substitute.
If you’re going to try omega-3, the trials with the cleanest signal use 1-3 g/day of EPA+DHA for at least three months. Track whether you actually notice a difference. If you don’t, stop.
❝ ✅ The Bottom Line
The biology of omega-3 reducing inflammation is real and measurable.
The clinical translation depends on the condition.
Modest signal for rheumatoid arthritis at higher doses; weak for osteoarthritis; none for spondyloarthritis based on current trials.
Randomized controlled trials were negative for dry eye disease; the AAO still considers it low-risk to try.
Supplement trials for AMD progression were negative but observational data on dietary fish intake remains favorable.
Best move for most readers: eat fish 2–3 times per week, target an Omega-3 Index above 8%, and reserve supplementation for specific situations rather than as a general anti-inflammatory move.
If you’re new to the series, start here: Welcome to Pareto Life and the Upcoming Series on Omega-3 intro. Then catch up on Issue 01 — Are Omega-3s good for everyone’s heart? and Issue 02 — Do Omega-3s reduce risk of dementia?.
Next week, we’ll close out the fish oil series with how to actually choose a product: EPA-to-DHA ratios, triglyceride vs. ethyl ester forms, and which “high-strength” labels are misleading.
References
Inflammation mechanism: Calder, Biochem Soc Trans 2017; umbrella meta-analysis of n-3 PUFA on inflammatory biomarkers (32 meta-analyses)
Rheumatoid arthritis: Sigaux et al., Arthritis Res Ther 2022; Wang et al., Clin Rheumatol 2024; Gkiouras et al., Crit Rev Food Sci Nutr 2023; Abdulrazaq et al., Nutrition 2017
Osteoarthritis: MacFarlane et al., Arthritis Rheumatol 2020 (VITAL knee-pain substudy); Laslett et al., JAMA 2024 (krill oil); Stonehouse et al., Am J Clin Nutr 2022; Bahamondes et al., Oral Surg Oral Med Oral Pathol Oral Radiol 2021
Spondyloarthritis: 2024 meta-analysis of 4 RCTs (245 patients)
Dry eye: Asbell et al., N Engl J Med 2018 (DREAM); Hussain et al., Cont Clin Trials 2019 (DREAM Extension); Christen et al., Am J Clin Nutr 2022 (VITAL-DED); AAO Preferred Practice Pattern, Dry Eye Syndrome
AMD: AREDS2 Research Group, JAMA 2013; Chew et al., JAMA Ophthalmol 2022 (AREDS2 Report 28, 10-year follow-up); NAT2 Study (Souied et al., Ophthalmology 2013); UK Biobank omega-3 / AMD analysis 2025; AAO Preferred Practice Pattern, AMD